|  |
| --- |
| **Table A7. Multivariate analysis for unfavorable risk cohort, matched** |
| Variable |  | HR(95%CI) | p-value |
| Treatment | EBRT+ADT | Reference |  |
|  | RP and PLND | 0.622(0.493-0.784) | 0.000 |
|  | EBRT+BT+ADT | 0.628(0.461-0.856) | 0.003 |
| Race | Black | Reference |  |
|  | White | 0.967(0.815-1.148) | 0.703 |
| Facility Type | Community Cancer Program | Reference |  |
|  | Comprehensive Community Cancer Program | 0.784(0.586-1.048) | 0.101 |
|  | Academic/Research Program | 0.854(0.628-1.160) | 0.312 |
|  | Integrated Network Cancer Program | 0.584(0.385-0.887) | 0.012 |
| Geography | New England |  |  |
|  | Middle Atlantic | 1.290(0.762-2.190) | 0.341 |
|  | South Atlantic | 1.510(0.906-2.521) | 0.114 |
|  | East North Central | 1.120(0.657-1.897) | 0.684 |
|  | East South Central | 1.410(0.803-2.482) | 0.231 |
|  | West North Central | 0.982(0.536-1.797) | 0.953 |
|  | West South Central | 1.130(0.610-2.104) | 0.693 |
|  | Mountain | 1.450(0.637-3.288) | 0.378 |
|  | Pacific | 1.270(0.723-2.226) | 0.407 |
| Insurance | Not Insured |  |  |
|  | Private Insurance | 1.430(0.529-3.878) | 0.480 |
|  | Medicaid | 2.200(0.717-6.774) | 0.168 |
|  | Medicare | 1.900(0.698-5.152) | 0.209 |
|  | Other Government | 1.570(0.469-5.259) | 0.464 |
|  | Insurance Status Unknown | 1.960(0.596-6.419) | 0.269 |
| Income | $38,000 - $47,999 |  |  |
|  | $48,000 - $62,999 | 0.804(0.637-1.016) | 0.068 |
|  | $63,000 + | 0.837(0.654-1.072) | 0.159 |
|  | < $38,000 | 0.862(0.675-1.101) | 0.233 |
| Charleson Deyo Comorbidity Index | 0 |  |  |
|  | 1 | 1.330(1.039-1.703) | 0.024 |
|  | 2 | 2.670(1.671-4.267) | 0.000 |
| Age |  | 1.030(1.017-1.047) | 0.000 |
| Diagnosis to treatment initiation time | 0-90 |  |  |
|  | >90 | 0.998(0.772-1.290) | 0.987 |
| Risk Cohort | HR | Reference |  |
|  | IR | 1.160(0.570-2.358) | 0.683 |
|  | VHR | 1.040(0.738-1.461) | 0.827 |
| clinical Gleason score | <=6 | Reference |  |
|  | 10 | 4.560(0.620-33.585) | 0.136 |
|  | 7 | 2.830(0.642-12.493) | 0.169 |
|  | 8 | 3.650(0.869-15.320) | 0.077 |
|  | 9 | 4.240(0.994-18.103) | 0.051 |
| PSA | <10 | Reference |  |
|  | >20 | 1.230(0.894-1.684) | 0.205 |
|  | 10-20 | 1.290(0.915-1.808) | 0.147 |
| clinical T stage | T1 | Reference |  |
|  | T2 | 1.220(0.986-1.515) | 0.067 |
|  | T3 | 1.600(1.186-2.154) | 0.002 |
|  | T4 | 1.680(0.688-4.108) | 0.255 |
| *Abbreviations: BT=brachytherapy; EBRT=external beam radiotherapy; RP=Radical Prostatectomy; PLND=Pelvic Lymph Node Dissection; SMD=Standardized mean difference; CI=Confidence Interval; fIR=favorable intermediate risk; LR=low risk* |
| *\* ng/mL* |
| *† combined Gleason score (excluding 4+3, or Gleason pattern 5)*  |